These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 12010863)

  • 1. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
    Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
    Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
    J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
    Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
    Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7.
    Höpfl R; Heim K; Christensen N; Zumbach K; Wieland U; Volgger B; Widschwendter A; Haimbuchner S; Müller-Holzner E; Pawlita M; Pfister H; Fritsch P
    Lancet; 2000 Dec; 356(9246):1985-6. PubMed ID: 11130532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
    Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
    J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.
    Luxton JC; Nath R; Derias N; Herbert A; Shepherd PS
    J Gen Virol; 2003 May; 84(Pt 5):1063-1070. PubMed ID: 12692269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma.
    Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Walboomers JM; Meijer CJ; Shah KV; Clayman B; Viscidi RP
    Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):935-40. PubMed ID: 10548324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer.
    Nindl I; Rindfleisch K; Lotz B; Schneider A; Dürst M
    Int J Cancer; 1999 Jul; 82(2):203-7. PubMed ID: 10389753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.
    Kadish AS; Romney SL; Ledwidge R; Tindle R; Fernando GJ; Zee SY; Van Ranst MA; Burk RD
    J Gen Virol; 1994 Sep; 75 ( Pt 9)():2277-84. PubMed ID: 8077925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
    Yang W; Song Y; Lu YL; Sun JZ; Wang HW
    Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.